Clinical trial

Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

NCT06144788

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2023-11-03

PhasePHASE2

Study timeline

Study start (actual)2023-11-03Date precision: day

Registry last updated2026-07-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetes Mellitusunresolved

Interventions

SGLT2 inhibitorDRUG

Sponsors & collaborators

Jeil Pharmaceutical Co., Ltd.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06144788 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.